TRUSELTIQ is indicated for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement as detected by an FDA-approved test. This indication received accelerated approval based on overall response rate and duration of response.
ONGENTYS® is indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing "off" episodes.
EMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
Neovascular (Wet) Age-Related Macular Degeneration (nAMD).
Diabetic Macular Edema (DME).
Macular Edema Following Retinal Vein Occlusion (RVO).
DATROWAY is indicated for adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (IHC 0, IHC 1+, or IHC 2+/ISH-) who have received prior endocrine-based therapy and chemotherapy in the metastatic or unresectable setting.
- How to Use Datopotamab deruxtecan (Datroway) Datopotamab deruxtecan (Datroway) is a Trop-2-targeted antibody-drug conjugate (ADC) indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
Oct 20, 2025, 11:46 GMT+08:00
- How to Purchase Datopotamab deruxtecan (Datroway) Datopotamab deruxtecan (Datroway) is a novel Trop-2-targeted antibody-drug conjugate (ADC) co-developed by Daiichi Sankyo Co., Ltd. and AstraZeneca. It is used for the treatment of patients with HR-positive/HER2-negative metastatic breast cancer.
Oct 20, 2025, 11:40 GMT+08:00
TRUSELTIQ is indicated for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement as detected by an FDA-approved test. This indication received accelerated approval based on overall response rate and duration of response.
ONGENTYS® is indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing "off" episodes.
EMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
Neovascular (Wet) Age-Related Macular Degeneration (nAMD).
Diabetic Macular Edema (DME).
Macular Edema Following Retinal Vein Occlusion (RVO).
DATROWAY is indicated for adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (IHC 0, IHC 1+, or IHC 2+/ISH-) who have received prior endocrine-based therapy and chemotherapy in the metastatic or unresectable setting.
VAFSEO is indicated specifically for the treatment of anemia due to chronic kidney disease in adult patients receiving dialysis for a minimum of three months.
- Indications for Odevixibat (Bylvay) Odevixibat (Bylvay) is an ileal bile acid transporter (IBAT) inhibitor, mainly indicated for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). It is a prescription drug and must be used strictly in accordance with the doctor's instructions.
503
2025-10-24 13:40:46 - How to Use Pramipexole Pramipexole is a non-ergot dopamine receptor agonist, mainly used for the treatment of Parkinson's disease (PD) and moderate-to-severe primary restless legs syndrome (RLS). Its efficacy and effectiveness are highly dependent on individualized medication regimens, and the dosage needs to be adjusted according to the patient's renal function, comorbidities, and treatment response. 502
2025-10-24 13:37:11
- Indications of Pomalidomide Pomalidomide is a thalidomide analog developed by Bristol-Myers Squibb. 503
2025-10-24 13:34:10
- How to Purchase Pramipexole Pramipexole is a non-ergot dopamine receptor agonist, primarily indicated for the treatment of Parkinson's disease and moderate-to-severe primary restless legs syndrome (RLS). Due to its unique pharmacological effects and strict medication requirements, patients must pay special attention to the legitimacy of purchase channels, identification of genuine vs. counterfeit drugs, and relevant contraindications when purchasing this medication. 502
2025-10-24 13:31:32
- How to Use Eliglustat (Cerdelga) Eliglustat (Cerdelga) is a selective glucosylceramide synthase inhibitor indicated for the long-term treatment of Type 1 Gaucher disease (GD1) in adults. Its efficacy and effectiveness are highly dependent on an individual's metabolic status and comorbidities. Therefore, it is essential to strictly follow the dosing regimen based on CYP2D6 metabolic phenotype and adjust the dose for special populations. 502
2025-10-24 13:28:50
- How to Use Pomalidomide Pomalidomide is a thalidomide analog classified as an immunomodulator. It is indicated for the treatment of multiple myeloma (MM) and Kaposi sarcoma (KS). Its use must strictly adhere to the principle of individualization, and attention should be paid to contraindications such as embryotoxicity and thromboembolic risk. 503
2025-10-24 13:04:45
- How to Use Pomalidomide Pomalidomide is a thalidomide analog and belongs to the class of immunomodulators. It is indicated for the treatment of multiple myeloma (MM) and Kaposi's sarcoma (KS). Its use must strictly adhere to the principle of individualization, and attention should be paid to contraindications such as embryotoxicity and thromboembolic risk. 503
2025-10-24 11:52:17
- What Are the Side Effects of Odevixibat (Bylvay)? Odevixibat (Bylvay) is a selective ileal bile acid transporter (IBAT) inhibitor, indicated for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). 503
2025-10-24 11:28:36
- Precautions for Odevixibat (Bylvay) Administration Odevixibat (Bylvay) is an ileal bile acid transporter (IBAT) inhibitor. It is indicated for the treatment of progressive familial intrahepatic cholestasis (PFIC)-related pruritus in patients aged 3 months and older, as well as cholestatic pruritus associated with Alagille syndrome (ALGS) in patients aged 12 months and older. 502
2025-10-24 11:26:07
- How to Use Odevixibat (Bylvay) Odevixibat (Bylvay) is an ileal bile acid transporter (IBAT) inhibitor used for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). Its efficacy and safety require individualized adjustment based on the patient’s age, body weight, and disease type. 502
2025-10-24 11:00:15
